Home > News > Invitrogen and Signalomics Collaborate to Develop Cancer Diagnostics
April 11th, 2006
Invitrogen and Signalomics Collaborate to Develop Cancer Diagnostics
Abstract:
Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced a collaborative agreement with Signalomics (Steinfurt, Germany) to develop nanocrystal reagents with the ability to enhance the identification of tumors in in vivo patient tissue by detecting the presence of a single cancerous cell -- improving the ability to excise the tumor more rapidly and completely.
Source:
businesswire
Bookmark:
Nanomedicine
Nanoparticle Harnesses Powerful Radiation Therapy for Cancer May 20th, 2013
Microneedle-Delivered Nanoparticles Boost Antitumor Vaccines May 20th, 2013
New Nanopore Sensor Simplifies Analysis of Methylated DNA May 20th, 2013
Elsevier Business Intelligence (EBI) to Host 'IN3 Medical Device 360 Boston,' June 24-26, 2013 May 20th, 2013
Materials
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Kinks and curves at the nanoscale: New research shows 'perfect twin boundaries' are not so perfect May 20th, 2013
Advancements and developments of solid-state nanopores sensors May 16th, 2013
Physicists discover a new kind of friction: Friction in the nano-world May 16th, 2013
Announcements
International survey supports need for built-in water protection on smartphones and tablets May 21st, 2013
Rice unveils method for tailoring optical processors: Arranging nanoparticles in geometric patterns allows for control of light with light May 21st, 2013
Iran to Hold 1st Conference on Applications of Nanotechnology in Energy Industry May 21st, 2013
Researchers Perform Fastest Measurements Ever Made of Ion Channel Proteins May 20th, 2013